ERBB2 and gastric cancer: A phase IIa trial studied the effect of the HER2‐targeted antibody pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2‐positive, advanced gastric cancer or cancer of the gastroesophageal junction.